

1 **Predicting experimental sepsis survival with a mathematical model of**
2 **acute inflammation**

3

4 **Jared Barber^{1*}, Amy Carpenter², Allison Torsey³, Tyler Borgard⁴, Rami A Namas^{5,6}, Yoram**

5 **Vodovotz^{5,6,†}, and Julia Arciero^{1,†}**

6

7 ¹Department of Mathematical Sciences, Indiana University-Purdue University Indianapolis,
8 Indianapolis, IN

9 ²Department of Natural Sciences and Mathematics, Lee University, Cleveland, TN

10 ³Department of Mathematics, SUNY Buffalo State, Buffalo, NY

11 ⁴Department of Mathematics, Purdue University, West Lafayette, IN

12 ⁵Department of Surgery, University of Pittsburgh, Pittsburgh, PA

13 ⁶Center for Inflammation and Regenerative Modeling, McGowan Institute for Regenerative
14 Medicine, University of Pittsburgh, Pittsburgh, PA

15

16 [†]Contributed equally as senior authors

17

18 ^{*}Corresponding Author

19 Email: jarobarb@iupui.edu

20 **Keywords:** mathematical modeling, acute inflammation, immune response, sepsis, *E. coli*

21

22

23

24

25

26

27 **Abstract**

28

29 Sepsis is characterized by an overactive, dysregulated inflammatory response that drives organ
30 dysfunction and often results in death. Mathematical modeling has emerged as an essential tool for
31 understanding these complex biological processes. A system of four ordinary differential equations
32 (ODEs) was developed to simulate the dynamics of bacteria, the pro- and anti-inflammatory
33 responses, and tissue damage (whose molecular correlate is damage-associated molecular pattern
34 [DAMP] molecules and which integrates inputs from the other variables, feeds back to drive further
35 inflammation, and serves as a proxy for whole-organism health status). The ODE model was
36 calibrated to experimental data from *E. coli* infection in genetically identical rats and was validated
37 with mortality data for these animals. The model demonstrated recovery, aseptic death, or septic
38 death outcomes for a simulated infection while varying the initial inoculum, pathogen growth rate,
39 strength of the local immune response, and activation of the pro-inflammatory response in the
40 system. In general, more septic outcomes were encountered when the initial inoculum of bacteria
41 was increased, the pathogen growth rate was increased, or the host immune response was decreased.
42 The model demonstrated that small changes in parameter values, such as those governing the
43 pathogen or the immune response, could explain the experimentally observed variability in mortality
44 rates among septic rats. A local sensitivity analysis was conducted to understand the magnitude of
45 such parameter effects on system dynamics. Despite successful predictions of mortality, simulated
46 trajectories of bacteria, inflammatory responses, and damage were closely clustered during the initial
47 stages of infection, suggesting that uncertainty in initial conditions could lead to difficulty in
48 predicting outcomes of sepsis by using inflammation biomarker levels.

49

50

51 **1 Introduction**

52

53 Sepsis is defined as life-threatening organ dysfunction caused by an overwhelming immune response
54 to an infection (1). Sepsis and septic shock often lead to organ failure and are leading causes of
55 morbidity and mortality (1, 2). In the course of a typical infection, pathogens (e.g., Gram-negative
56 bacteria) infect the host, triggering a pro-inflammatory innate immune response targeted at
57 eliminating the pathogen from the system. The body also mounts an anti-inflammatory response that
58 works to maintain homeostasis and prevent overwhelming inflammation to the system. The acute
59 inflammatory response in sepsis becomes detrimental when it can no longer be contained at the locus
60 of infection (where innate immune mechanisms can help eliminate bacteria) and becomes systemic,
61 leading to collateral damage/dysfunction in the surrounding healthy tissue. Thus, a major goal in
62 sepsis research is to determine why the host mounts an overwhelming inflammatory response to
63 infections which leads to sepsis in some cases but not in others (3, 4).

64

65 Acute inflammatory responses to infection are further complicated by additional variations among
66 sepsis patients (5), the complex interplay between pro- and anti-inflammatory mediators and the
67 innate and adaptive immune responses (6), and a triphasic distribution of patient deaths that occur
68 days, weeks, and years after initial infection (6). These variations have highlighted the need for
69 patient-specific treatments and novel approaches to sepsis drug design and clinical trials (7-9).

70

71 Recent decades have brought about improved sepsis treatment practices, including the rapid
72 administration of antibiotics, infection source control, appropriate choice of fluid (crystalloids) for
73 fluid resuscitation, and administration of vasopressors (norepinephrine) (10). These evolutionary

74 improvements in patient care have reduced in-hospital mortality but have shifted the mortality
75 distribution so that most sepsis-related deaths occur months after treatment (6). While improved care
76 often allows patients to overcome initial septic episodes, it has been speculated that underlying
77 physiologic/biochemical aberrations combined with sepsis-initiated immune dysfunction place
78 patients at long-term risk for sepsis mortality (11). Secondary infections occurring during late stages
79 (> 15 days) were shown to correlate with higher levels of opportunistic fungi and bacteria compared
80 to earlier secondary infections (< 6 days) (12), and impairments in immune function and cytokine
81 secretion were observed in individuals that survived a septic episode (13). Despite evidence of late-
82 stage complications or mortality from sepsis (14), mortality is still common within a week of sepsis
83 onset; interventions in those cases rely on early identification of septic trajectories, which is often
84 difficult.

85

86 Given the complexities of infection and inflammation *in vivo* and *in vitro*, mathematical modeling
87 has been used in an attempt to unravel the complexities of inflammation and the immune response (8,
88 9, 15-17). Multiple mechanistic computational models have described the dynamics of the
89 inflammatory response in the context of a variety of bacterial infections (18-20). These include
90 equation-based (ordinary (16, 17, 21-35) and partial differential equations (36, 37)), agent-based (38-
91 40), and hybrid models (41). Although some models are purely theoretical (16, 17, 21, 37, 40), many
92 were calibrated to experimental data in animals (23-25, 28-30) or attempted to replicate clinical
93 outcomes (26, 38, 39, 42).

94

95 The current study implemented a mechanistic model of the immune response to an *Escherichia coli*
96 (*E. coli*) infection and aimed to determine whether early data on both the pathogen and the host
97 response are sufficient to predict a health or disease outcome. A parsimonious system of four
98 ordinary differential equations (ODEs) was used to track changes in bacteria, tissue damage, a pro-
99 inflammatory response, and an anti-inflammatory response following the administration of escalating
100 inocula of *E. coli* encapsulated in a fibrin clot (an experimental model of Gram-negative
101 peritonitis (43)) in rats. Ultimately, the mathematical model defined in this study was used to
102 evaluate and predict the time dynamics of the bacterial infection, which were observed to vary
103 depending on the initial bacterial dose. The model demonstrated that small changes in the pathogen
104 growth rate or characteristics of the immune response could lead to significantly different mortality
105 times despite identical initial bacterial loads.

106

107 **2 Materials and Methods**

108

109 **2.1 Experimental Method**

110

111 **2.1.1 Preparation and Dose Estimation of *E. Coli*-Impregnated Fibrin Clot**

112 All animal studies were carried out following approval by the University of Pittsburgh Institutional
113 Animal Use and Care Committee (IACUC approval #0807947) and complied with the NIH Guide for
114 the Care and Use of Laboratory Animals. In this study, experimental data were obtained from rats
115 with peritonitis induced by an *E. Coli*-impregnated fibrin clot, similar to the methods established by
116 Ahrenholz *et al.* (43) and modified by Namas *et al.* (44). In brief, the animals were subjected to a
117 varying dose of *E. Coli* (strain ATCC 25922; American Type Culture Collection, Manassas, VA,

118 USA) inoculum in a fibrin clot introduced into the peritoneum via laparotomy. The *E. Coli* colonies
119 were grown to a specified optical density using a spectrophotometer (DU 530 UV/VIS; Beckman
120 Coulter, Brea, CA, USA) equivalent to a concentration ranging between 1×10^8 to 5×10^8 colony-
121 forming units [CFUs]/clot on the day of bacterial fibrin clot implantation. After the addition of
122 fibrinogen (1%) and Thrombin (15u), the clot was placed in the peritoneum via laparotomy, as
123 described previously (44). Since quantification of bacteria at the time of implantation of the fibrin
124 clot via optical density is highly imprecise, bacteria were quantified after each implantation by
125 limiting dilution plating to obtain a count of implanted *E. coli* in a given rat (44).

126

127 We determined that rats that received a fibrin clot inoculum of 1×10^8 to 2.0×10^8 CFUs/clot had a
128 mortality rate of ~40–45% after 48 h of clot implantation while rats that received inocula higher than
129 2.0×10^8 CFUs/clot had a mortality rate of 80% during the first 24 h of implantation (data not
130 shown). All rats in these experiments exhibited signs of septicemia in the form of lethargy,
131 hypothermia, reluctance to feed, tachycardia, and tachypnea after 24 h of *E. Coli* fibrin clot
132 impregnation into the peritoneum. After closing the abdomen, a topical anesthetic was applied over
133 the surgical wound, and the rats were returned to their cages and allowed food and water *ad libitum*.

134

135 2.1.2 Model Calibration and Validation

136

137 The experimental studies detailed above generated one experimental data set that was used to
138 calibrate the model and consisted of measurements of bacterial levels at different timepoints in 31
139 rats injected with increasing doses of bacteria (1.28 , 2.48 and 5.05×10^8 bacteria with standard error

140 of the mean of 1.5×10^7 , 2.8×10^7 , and 1.2×10^8 , respectively). A second (separate) experimental
141 data set was used to validate the model and consisted of time to death (mortality; 24, 48, 72, or 96 h)
142 for 27 rats injected with varying doses of bacteria ($1-5 \times 10^8$ bacteria). We detail the process of
143 model calibration and validation below.

144

145 Bacterial levels in the peritoneal cavity measured in individual septic rats, each euthanized at a
146 distinct time point from 24-96 h after being impregnated with $\approx 1 \times 10^8$ to 5×10^8 colony-forming
147 units of *E. coli*, were used to calibrate the model (“calibration data set”, see Fig 1A and Table S1).
148 Observed times to mortality for rats injected with $\approx 1.4 \times 10^8$ to 4.8×10^8 colony-forming units of *E.*
149 *coli* were used to evaluate the predictive capabilities of the ODE model (“validation data set,” see Fig
150 1B and Table S2). These two data sets were derived from two different rat populations.

151

152 The calibration data set (Fig 1A and Table S1) was produced using several experiments involving
153 multiple rats in each experiment and three different bacterial levels with mean values of 1.28×10^8 ,
154 2.48×10^8 , and 5.05×10^8 bacteria. A peritoneal lavage was used to assess the number of bacteria in
155 the peritoneal cavity in each individual animal euthanized at one of the time points indicated in Table
156 S1, as detailed in (44). This produced an estimate for the expected bacterial levels over time in a rat
157 subject to one of the targeted loads, as seen in Fig 1A. The time points were chosen to be closer
158 together for rats injected with higher bacterial loads, since these animals were more likely to die
159 earlier than animals receiving a lower bacterial inoculum.

160

161 In the validation data set (Fig 1B and Table S2), the rats were monitored continuously until 96 h, at
162 which time surviving rats were euthanized. If a rat was observed to be dead at a 24-h checkpoint (24,
163 48, 72, or 96 h), that time point was noted as the “observed mortality time” (OMT) for that rat and
164 the rat was removed from the study. Rats labeled with an OMT = 24, 48, or 72 h either died within
165 the 24 h before their OMT or were euthanized at their OMT (in accordance with IACUC and NIH
166 guidelines) due to being severely unhealthy. Rats labeled with a 96 OMT either died between 72 and
167 96 h, were severely unhealthy at 96 h, or were relatively healthy at 96 h. Given these distinctions, it
168 is possible that some of the 96 h OMT rats would have survived longer.

169

170 Fig 1B depicts the mortality data set (closed circles, ●) collected for 27 rats with the observed
171 mortality time on the x -axis and the initial bacterial load on the y -axis. A Bartlett test revealed that
172 the variances of the four groups (OMT = 24, 48, 72, 96 h) were not significantly different (p -value =
173 0.689) while ten out of ten normality tests (45) on the deviations in the data from their respective
174 group norms were passed, suggesting that the data in each group are approximately normally
175 distributed. Analysis of variance (ANOVA), which assumes normally distributed data with equal
176 variances across groups, was then performed to show that the initial bacteria levels for the three OMT
177 = 48-, 72-, and 96-h groups with OMT > 24 h were not significantly different from each other (p -
178 value = 0.251). More specific delineation of the health and disease status of the rats in the 96-h
179 group may have led to more variance between the OMT = 48-, 72-, and 96-h groups, but those data
180 were not available at the time of this study. ANOVA on all four groups and use of Tukey’s
181 procedure with 95% confidence intervals suggested that the OMT = 24-h group had significantly
182 different levels of initial bacterial load compared to the OMT = 48-, 72-, and 96-h groups (p -value <
183 0.0051). The analysis was performed with Matlab (*normalitytest* (45) and Matlab’s *vartestn*, *anova1*,

184 and *multcompare*; Matlab code available via Github, see Supplementary Information), and the
185 resulting conclusions regarding the differences between the groups were consistent with the
186 relationships suggested by the box and whiskers plot shown in Fig 1B. The analysis suggested that
187 there were effectively only two different experimental groups: rats with OMT = 24 h and rats with
188 OMT > 24 h. These two categories were therefore used when assessing the predictive capabilities of
189 the model.

190

191 **2.2 Model and simulations**

192 **2.2.1 Model variables and interactions**

193 The mathematical model developed in this sepsis study was based on previous models of the immune
194 response (16, 21, 36, 46, 47). It was used to predict the dependence of health or disease outcomes on
195 pathogen properties and the immune response. Following the administration of *E. coli* inoculum into
196 the peritoneum, the model was used to predict changes in the number of bacteria in the peritoneal
197 cavity of the animal (B), the level of tissue damage (ε), a pro-inflammatory response (M), and an
198 anti-inflammatory response (A). Tissue damage serves as a proxy for whole-organism health status.
199 *In vivo*, the molecular correlates to tissue damage are damage-associated molecular pattern [DAMP]
200 molecules such as high-mobility group box 1 (HMGB1) (48, 49). Due to limited calibrating data and
201 a desire for model simplicity, the numerous cells and cytokines that generate the pro- and anti-
202 inflammatory responses were grouped into two general populations, as in previous models (16, 46,
203 50). Specifically, tissue-specific effects of bacterial infection were assumed to be driven by both
204 resident tissue macrophages and inflammatory cells such as neutrophils and macrophages that
205 infiltrate the tissue from the blood (51-54). Nominally pro-inflammatory cytokines (e.g., TNF, IL-
206 1b, IFN- γ , IL-17A) and anti-inflammatory cytokines (e.g., TGF- β 1, IL-10, IL-4, IL-13) were not

207 measured in these experiments, and therefore these cytokines (along with a multitude of chemokines
208 and DAMPs) were grouped into general populations whose effects were assumed independent of
209 inflammatory mediator type.

210

211 Fig 2 provides a schematic of the assumed interactions (54) among model populations (schematic
212 adapted from (16)). A time-dependent dosing function, $D(t)$, defines the release of bacteria from the
213 clot into the surrounding tissue. In response, pro-inflammatory cells activate and begin to destroy the
214 bacteria while also causing collateral tissue damage and promoting self-recruitment. Both pro-
215 inflammatory cells and tissue damage trigger an anti-inflammatory response, which in turn inhibits
216 the growth of the pro-inflammatory response and damage levels. These interactions are labeled in
217 Fig 2 with arrow heads indicating upregulation and blunted ends indicating downregulation.

218

219 Although it is nearly impossible to state that no other model could account for the variables and
220 interactions depicted in Fig 2 (55), the approach utilized in this study adapted previous models (16,
221 46) of bacterial infection that were successful at reproducing multiple physiological behaviors. The
222 current model was based on clear assumptions, including ones that stemmed from the experimental
223 technique for bacterial administration into the rats. More specifically, Ahrenholz and Simmons (43)
224 originally used the experimental method implemented in this study to consider the theory that
225 increased fibrin levels decrease the severity of infections during *E. coli* peritonitis. Namas et al. (44)
226 used the same procedure to explore the effectiveness of hemadsorption techniques on treating septic
227 peritonitis. They performed several initial experiments in which they injected rats with fibrin clots
228 containing varying levels of bacteria. The rats usually died or resolved in a relatively short amount

229 of time, so only the acute immune response was assumed to play a significant role in infection
 230 dynamics. Additionally, the experimental technique for bacterial administration introduced bacteria
 231 more gradually into the system than instantaneous bacterial injection into the blood. Both
 232 observations played a significant role in the modeling choices employed here.

233

234 **2.2.2 Model equations**

235 The rate of change of the number of bacteria in an animal is governed by Equation 1:

236

$$237 \frac{dB}{dt} = D(t) + k_1 B \left(1 - \frac{B}{B_\infty/B_s}\right) - \frac{k_2 s_l B}{\mu_l + k_3 B_s B} - \frac{k_5 B M}{1 + k_A A} \quad (1)$$

238

239 The first term, $D(t)$, defines the release of bacteria from the fibrin clot as an exponentially decaying
 240 dosing function given by $D(t) = D_1 \exp(-k_D t)$. The second term corresponds to logistic growth of
 241 bacteria with growth rate k_1 . The third term corresponds to a non-specific, local, innate immune
 242 response that is assumed to eliminate a small amount of pathogen without activating a full systemic
 243 inflammatory response (16). The details of the parameter value derivation for this term are given in
 244 (16). The final term defines the elimination of bacteria by the systemic pro-inflammatory response,
 245 which is inhibited by systemic anti-inflammation.

246

247 As a first-order approximation, all bacteria initially in the clot were assumed to empty into the
 248 surrounding tissue without reproducing or dying, which is equivalent to $\int_0^\infty D(t) dt$
 249 $= \int_0^\infty D_1 \exp(-k_D t) dt = B_{source}$, where B_{source} is the initial amount of bacteria in the fibrin clot (B_{source}

250 $= 128 \times 10^6$, 248×10^6 , or 505×10^6 bacteria in the calibration data set). To satisfy this condition
 251 for the conservation of clot bacteria, D_I must equal $k_D B_{source}$. B was also scaled by a factor B_s (see
 252 Section 2.3) to account for the difference in bacterial levels between the rat experiments described in
 253 this study and the bacteria levels considered in the previous (human) models (16). This factor also
 254 converts number of bacteria to concentration of bacteria (bacteria/cm³) and allows previous
 255 parameter values (16, 46) to be used here.

256

257 We note that multiple dosing functions were considered before choosing the exponential decay
 258 model. For example, an additional variable tracking the bacterial levels inside the clot was
 259 introduced and allowed to experience growth and/or transfer between the clot and surrounding tissue.
 260 Despite providing three additional degrees of freedom, this alternate approach did not yield model
 261 fits that were significantly better than using a simple exponential function to define the rate at which
 262 bacteria emptied into the surrounding tissue. We also explored making parameter k_d a saturating
 263 sigmoidal function of B_{source} , since experimental observations suggested that a clot with a small
 264 number of bacteria had a slower release rate than a clot containing a large inoculum of bacteria. This
 265 assumption, however, also did not lead to improved model fits. Thus, an exponential function with
 266 constant rate of decay, k_d , was implemented in the model and yielded reasonable fits to the data.

267

268 Equation 2 defines the rate of change of the systemic pro-inflammatory response (M):

$$269 \frac{dM}{dt} = \frac{\nu_1 f(M, B, \epsilon)}{(\nu_2 + f(M, B, \epsilon))(1 + k_A A)} - \mu_M M. \quad (2)$$

270 where $f(M, B, \epsilon) = k_M M + k_B B_s B + k_\epsilon \epsilon$. The pro-inflammatory response is increased by pro-
 271 inflammatory cells, bacteria, and damage and is inhibited by the systemic anti-inflammatory
 272 response. Natural decay of the response occurs at rate μ_M . Recruitment of inactive pro-inflammatory
 273 cells occurs at a rate proportional to v_1 , as given in (16, 21). The possible effect of LPS inflicting
 274 toxicity (without any bacteria present) has been subsumed into the parameter values for the onset and
 275 persistence of inflammation as a consequence of bacterial infection. T helper 1 cells (Th1) and T
 276 helper 17 cells (Th17) are also assumed to be included in model population M .

277

278 The rate of change of the anti-inflammatory response (A) is defined in Equation 3:

$$279 \quad \frac{dA}{dt} = s_A + \frac{v_3(M + k_4\epsilon)}{(v_4 + M + k_4\epsilon)(1 + k_A A)} - \mu_A A. \quad (3)$$

280 The first term accounts for the nonzero background level (s_A) of anti-inflammatory mediators that
 281 resides in the body. In the second term, the pro-inflammatory response and damage activate the anti-
 282 inflammatory response. The anti-inflammatory response also self-regulates, which is modeled using
 283 the $(1+k_A A)$ term in the denominator. Natural decay of the response occurs at rate μ_A .

284

285 The final model equation (Eq. 4) gives the rate of change of tissue damage levels (ϵ):

$$286 \quad \frac{d\epsilon}{dt} = -\frac{\epsilon}{\tau} + \frac{[fM - T]_+}{1 + k_A A}. \quad (4)$$

287

288 In the first term, damage is repaired at rate $1/\tau$. In the second term, similar to (46), it was assumed
 289 that the system can tolerate a certain level of inflammation before pro-inflammatory cells begin
 290 causing damage. This assumption is represented using a threshold function:

291

292
$$[fM - T]_+ = \begin{cases} fM - T & (fM - T) > 0 \\ 0 & \text{otherwise} \end{cases}. \quad (5)$$

293 T gives the threshold above which immune cells begin to cause damage in the nearby tissue, and f

294 gives the rate at which the cells cause damage.

295

296 **2.2.3 Initial conditions**

297

298 At the onset of each simulation, the rats were assumed to be healthy, corresponding to initial
 299 conditions of $B(0) = 0$, $M(0) = 0$, $A(0) = s_A/\mu_A$, and $\varepsilon(0) = 0$. Since animals exhibit background levels
 300 of anti-inflammatory mediators (e.g., transforming growth factor- β 1 (56)), nonzero initial
 301 background levels of anti-inflammatory response mediators were assumed. Parameter B_{source}
 302 corresponds to the number of bacteria inserted into the clot for each experiment and controls the
 303 magnitude of the dosing function, $D(t)$. Thus, B_{source} was changed in each simulation (i.e., for each
 304 rat) to correspond to the experiment being modeled.

305

306 For high enough B_{source} , it was observed that the clots were highly saturated to the point that bacteria
 307 left the clot nearly instantaneously. To model this, $B(0)$ was set to $B_{source} - B_c$, where B_c is a fitted
 308 parameter thought of as the “clot capacity.” This assumes the number of bacteria that exceed B_c
 309 instantaneously enter the surrounding tissue. With only B_c bacteria assumed to remain in the clot
 310 after the initial injection, the dosing function is adjusted to depend only on those bacteria (B_c)
 311 remaining in the clot: $D(t) = k_D B_c \exp(-k_D t)$.

312

313 **2.3 Parameter values**

314 Table 1 provides the values, units, and sources for all twenty-six model parameters. Because of the
315 lumped nature of variables M , A , and ε , general units (“ M -units”, “ A -units”, and “ ε -units”) were used
316 to describe these populations, as treated previously (16, 36, 46). To be consistent with experimental
317 measures, the units for bacteria were given as 10^6 bacteria. Several parameter estimation techniques
318 were utilized to yield maximum parameter estimation efficiency and physiologically realistic results.

319

320 The unknown parameter space dimension was decreased by estimating several parameter values
321 using previous studies. Following Reynolds et al. (16), k_A was chosen so that anti-inflammatory
322 inhibition is at most 75% (57), and μ_A was chosen to be significantly smaller than typical cytokine
323 decay rates (58-61) because these cytokines have longer lasting downstream effects in the anti-
324 inflammatory cascade. The quality of the parameter fit varied relatively little (<0.1%) when
325 parameter T was allowed to vary. Choosing T too large made $[fM - T]_+ = 0$ for all simulations while
326 choosing T too small made $[fM - T]_+ \approx fM$, which violates the assumption that the system can tolerate
327 a certain *significant* level of inflammation (46). Setting T to 1 avoided both extremes without
328 affecting fit quality.

329

330 Seven parameters remained that still had relatively high levels of uncertainty regarding their values.
331 Those parameters (B_∞ , f , k_D , B_s , v_4 , B_c , and k_1) were estimated using a constrained least squares
332 optimization on log-transformed data. The fit was constrained based on qualitative observations
333 regarding the general inflammation paradigm where typically one of three qualitative outcomes occur
334 (54). In the first type of outcome, termed “healthy recovery,” individuals are affected by an
335 infection, but their inflammatory response is quick and successfully eliminates the infection. In the

336 second type of outcome, termed “aseptic death,” the inflammatory response eliminates many of the
337 bacteria but overwhelms surrounding healthy tissue until death occurs. In the third type, termed
338 “septic death,” large numbers of bacteria survive alongside a mounting inflammatory response and
339 death results. Typical dynamics in other studies (16-18, 21) suggest that lower initial pathogen levels
340 often produce healthy recovery outcomes, mid-level initial pathogen levels often produce aseptic
341 outcomes, and high levels produce septic outcomes. To produce a model capable of similar behavior,
342 the optimization process was constrained so that simulated rats injected with 128×10^6 bacteria
343 experienced healthy recovery outcomes, simulated rats injected with 248×10^6 bacteria experienced
344 aseptic outcomes, and simulated rats injected with 505×10^6 bacteria experienced septic outcomes.
345 Such an approach is supported by the following assumptions: (i) the relatively good fit to the data
346 ($R^2 = 0.70$); (ii) relatively low levels of bacteria ($O(10^6)$) in the 248×10^6 initial bacterial load
347 calibration experiments after 72 h (i.e., probably not septic); (iii) persisting high levels of bacteria
348 ($O(10^7)$) in the 505×10^6 initial bacterial load calibration experiments after 48 h (i.e., probably
349 septic); and (iv) high mortality rates for loads above 200×10^6 bacteria (44). The large range of
350 measured bacterial levels suggested that log-transforming the data was also reasonable. Importantly,
351 the standardized residuals associated with the log-transformed measurements and simulated data (Fig
352 3B) passed ten out of ten normality tests (45). Similar outcomes were not possible for data that were
353 not log-transformed.

354

355 In the optimization procedure, the following squared residuals of the log-transformed data were
356 minimized:

357
$$\sum_{i=1}^{N_m} (\log(y_i) - \log(\hat{y}_i))^2 \quad (6)$$

358

359 where y_i corresponds to all experimentally measured bacterial levels at the time points and initial
360 bacterial loads listed in Table S1, \hat{y}_i corresponds to the model-predicted bacterial levels at the same
361 time points and initial bacterial loads, and $N_m = 31$ is the total number of measurements. Although a
362 range of values for k_2 and v_1 are later used to assess their effects on system dynamics (see Fig 8),
363 during the optimization, and by default unless otherwise stated, k_2 and v_1 were set to 0.6 1/ M -units/h
364 and 0.08 M -units/h, respectively, to be consistent with the values used in Reynolds et al (16).
365 Parameter k_1 was fit during the optimization procedure to yield its default value of $k_1 = 1.27/h$; this
366 value was used throughout the study except when assessing the impact of varying this parameter (Fig
367 8). Multiple standard optimization techniques were used during the process to ensure the finding of a
368 reasonable optimum, including the Nelder-Mead simplex method, the steepest descent algorithm, and
369 random restarts (Matlab code available via Github, see Supplementary Information). The resulting
370 parameter estimates are given in Table 1.

371

372 **2.4 Sensitivity calculation**

373

374 Due to the high dimension of parameter space (26 parameters) and the relatively small amount of
375 data (18 independent time points), only a small subset of the parameters should be optimized at any
376 given time to avoid excessive computations and identifiability issues. Identifiability is discussed
377 later in this section but briefly, the larger the number of fitted parameters, the more likely we will
378 encounter an unidentifiable parameter set where multiple sets of parameter values can be used to
379 produce the exact same optimal fit quality. Having no unique optimal parameter set can cause
380 traditional optimization techniques to fail. Here, seven parameters were chosen to be fit based on
381 their associated levels of uncertainty. It is possible that improved fits could be obtained by choosing
382 a different parameter set (e.g., by fixing some of the fit parameters to other estimates found in the

383 literature (16)). In addition, while calibrating the model to a given data set will limit the general
 384 dynamics that a model may exhibit, it is possible that multiple optimal parameter sets exist whose
 385 dynamics significantly differ.

386

387 To explore (i) the suitability of the current model, (ii) the set of fit parameters, and (iii) the possible
 388 effects of varying other parameters, a local sensitivity analysis around the current best fit was
 389 performed. The relative sensitivities, s_{ij} , of the i^{th} simulated measurement (\hat{y}_i) with respect to the j^{th}
 390 parameter (p_j) were estimated using the relative change in \hat{y}_i divided by the relative change in the
 391 parameter value:

$$392 \quad s_{ij} = \frac{\left(\frac{\hat{y}_i(p_j + p_j \delta_j) - \hat{y}_i(p_j)}{\hat{y}_i(p_j)} \right)}{\left(\frac{(p_j + p_j \delta_j) - p_j}{p_j} \right)} = \left(\frac{\hat{y}_i(p_j + p_j \delta_j) - \hat{y}_i(p_j)}{\delta_j \hat{y}_i(p_j)} \right) \quad (7)$$

393

394 In Eq. 7, the magnitude of δ_j is chosen to be the square root of machine epsilon. For some
 395 parameters, differently signed δ_j 's would alter the original simulation outcomes (healthy recovery,
 396 aseptic, septic). While such changes can happen in reality, this results in significant jumps in
 397 simulated measurement values and complicates the analysis. A complete analysis should consider
 398 behavior both when such jumps occur and when they do not and average the results. To include all
 399 parameters in the jump data analysis, δ_j would need to be altered so that all parameters experience
 400 such jumps. Since the jumps are typically of approximately the same size, an alternate strategy
 401 would need to be developed to compare these similarly sized jumps. Because of such complications,
 402 only sensitivities with no outcome behavior changes were considered here. At the same time, we

403 note that larger calculated values of $|s_{ij}|$ (calculated in the absence of outcome changes) correlate well
 404 with increased likelihood of these more significant outcome changes. To gauge the general
 405 sensitivity of all measurements to particular parameters and to understand how much a given
 406 parameter may affect outcomes, the root mean squared sensitivity (RMSS, S_i) was calculated:

$$407 \quad S_i = \sqrt{\frac{1}{N_m} \sum_{i=1}^{N_m} s_{ij}^2} \quad (8)$$

408 where $N_m = 31$ gives the number of measurements made in the calibrating data set. This sensitivity
 409 value (S_i) is provided in Table S3 and provides an estimate for the relative importance of each
 410 parameter in the model fitting process with higher sensitivities corresponding to parameters that
 411 affect the fit and corresponding dynamics more. Better and quicker fits tend to result when
 412 parameters are more sensitive. For any given set of parameters, a sum of their RMSSs can give an
 413 estimate to how sensitive the measurements are to that specific parameter set.

414

415 Identifiability is another important consideration when assessing how parameter values affect system
 416 dynamics. As an example, model parameters k_2 and s_l are not identifiable from the data because
 417 increasing k_2 by 1% will produce the exact same change in the variable outputs as increasing s_l by
 418 1%. This is because they only appear in the model as $(k_2 \cdot s_l)$, never separately elsewhere. In such
 419 scenarios, it is impossible to identify the values of such parameters without additional outside
 420 information, as was the case in (16). Studying the identifiability of a large set of parameters with an
 421 associated nonlinear system can be difficult. While standard linear algebra methods can be used for
 422 linear systems (62, 63), nonlinear systems require more specialized and often more computationally
 423 and theoretically intensive approaches such as methods utilizing rational functions (64), methods
 424 focusing on local expansions or transformations (63), and methods centering on observability (65).

425 Here we employed a local analysis, including linearization about the current model's parameter
 426 values, to consider the issue of identifiability. In the local analysis, identifiability is investigated by
 427 considering the collinearity of the parameters, where the effects of changing one parameter can be
 428 reproduced by a linear combination of changes in the other parameters. In such cases, parameters
 429 can be redundant, with their variations capable of being reproduced by changing the other
 430 parameters. The idea of collinearity can be written in terms of the previously mentioned sensitivities:
 431 $s_{ik} = \sum_{j \neq k} \alpha_j s_{ij} \forall i$. A corresponding collinearity index can be defined as: $CI_k = 1/\sigma_{\min}$ where σ_{\min} is the
 432 smallest singular value of the associated sensitivity matrix defined by components s_{ij} (66). Lower
 433 collinearity indices indicate more weakly correlated parameters that better describe the local
 434 parameter space and typically produce better overall fits and corresponding calibrated models. Such
 435 analysis identifies parameters sets that should not be used for fitting (high CI_k values) because of the
 436 possible presence of redundant parameters. The index can also be used to identify sets of parameters
 437 that may produce better fits.

438

439 **3 Results**

440

441 **3.1 *Bacterial infection model dynamics reproduce key sepsis outcomes***

442

443 The bacterial infections simulated in this study led to three possible outcomes: healthy recovery,
 444 aseptic death, or septic death (16). In this model, a healthy recovery outcome corresponds to a return
 445 to a steady state where pathogenic bacteria are fully eliminated ($B = 0$) and tissue damage levels
 446 return to baseline pre-infection levels ($\varepsilon = 0$). Aseptic death occurs when the bacteria are cleared (B
 447 = 0) but damage levels remain elevated ($\varepsilon > 0$). Septic death results when bacteria levels ($B > 0$) and
 448 damage ($\varepsilon > 0$) remain elevated at steady state.

449

450 In Fig 4, all three outcomes were predicted to occur given the same level of initial bacterial dose
451 ($B_{source} = 128 \times 10^6$ bacteria) but for three different levels of pathogen growth rate, k_1 . For a low
452 pathogen growth rate ($k_1 = 1.2/h$), the pro-inflammatory response eliminated the bacteria, and healthy
453 recovery (B/B_{max} , M/M_{max} , $(A-A_{healthy})/A_{max}$, and $\varepsilon/\varepsilon_{max}$ all less than 1%) was predicted to be restored
454 by 37 h (cyan curve). For a slightly higher pathogen growth rate ($k_1 = 1.3/h$), the pro-inflammatory
455 response also eliminated the bacteria, but caused an elevated and sustained inflammatory response
456 corresponding to aseptic death (blue curve) due to a forward-feedback loop of inflammation →
457 damage → inflammation (44). For a high pathogen growth rate ($k_1 = 1.4/h$), the pro-inflammatory
458 response was incapable of eliminating the bacteria, so bacterial levels, damage, and the anti-
459 inflammatory response all remained elevated at the steady state (corresponding to septic death, red
460 curve).

461

462 3.2 *Sensitivity analysis supports choice of initial model parameters*

463

464 Calculating local collinearities and sensitivities allowed for the identification of other parameter sets
465 that are better (from a sensitivity and collinearity point of view) than the best fit identified in this
466 paper. As an example, k_D , B_s , B_c , k_1 , k_2 , μ_l , and s_A have a sum of RMSSs of 137 and a collinearity
467 index of 17 while the fit used in this paper has a sum of RMSSs of 62 and a collinearity of 55 (less
468 sensitive and more collinear). Despite worse metrics, optimization of this alternative parameter set
469 (originally suggested by our local sensitivity and collinearity analyses) did not significantly improve
470 the overall parameter fit (R^2 still approximately 0.70). This suggests that the parameters currently

471 chosen for the model fitting are reasonable despite lower sensitivities and higher collinearities
472 compared to other parameter sets.

473
474 The values of RMSS (Table S3) showed that the model results are most sensitive to local immune
475 response parameters (i.e., s_l , k_2 , μ_l and k_3) and second-most sensitive to pathogen and dosing related
476 parameters (i.e., k_1 , k_D , B_s , B_{inf}). The other parameters affecting the inflammatory response and
477 damage displayed lower sensitivities.

478
479 **3.3 Comparison of model simulations and experimental data suggest a high mortality**
480 ***prediction capacity***

481
482 Prior studies utilizing reduced models of sepsis-induced inflammation were not docked to data,
483 especially with regard to the level or trajectory of the damage variable that equated with death (16,
484 17, 21). To address this shortcoming, we compared the behavior of the damage variable in our model
485 to mortality observations in an experimental model of Gram-negative bacterial sepsis.

486
487 In Fig 5A, the ability of the model to use damage levels to predict deaths occurring within 24 h
488 (OMT = 24 h) and deaths occurring after 24 h (OMT > 24 h) was quantified by comparing damage-
489 based predictions of the mathematical model with the experimental observations in the validation
490 data set. Using the mathematical model, the time of death (i.e., mortality time), t_c , for a simulated rat
491 was assumed to be the model-predicted time at which the value of the damage variable, ε , reached a
492 critical damage level (ε_{crit}). If $t_c \leq 24$ h, the rat was predicted to die within 24 h and to belong to the

493 OMT = 24-h group. Similarly, if $24 < t_c \leq 48$, the model-predicted value for the OMT was 48 h and
494 the rat was predicted to belong to the OMT > 24-h group. The initial levels of bacteria given to each
495 rat from the validation data set (27 total) were used as inputs to the calibrated model to yield model
496 predictions for survival time (OMT = 24 h or OMT > 24 h) for each rat in the study. Model accuracy
497 was defined as the ratio of correct predictions to total number of predictions. Both the predictions
498 and model accuracy are functions of ε_{crit} , as shown in Fig 5A. A relatively high level of accuracy (>
499 80%) was found for a wide range of critical damage levels ($49.2 \leq \varepsilon_{crit} \leq 123.4$ ε -units). A maximum
500 accuracy of 96% was attained for ε_{crit} values between 49.8 and 55 ε -units.

501

502 As an additional assessment tool of the predictive capability of the model, an area under the curve-
503 receiver operating characteristics (AUC-ROC) curve was constructed (Fig 5B). In this figure, a
504 positive outcome or identification corresponds to death occurring within 24 h. As such, ‘true
505 positive’ corresponds to a model prediction agreeing with an experimental observation of a rat that
506 dies within 24 h, while ‘false positive’ corresponds to a model prediction of a rat dying within 24 h
507 when the experiment indicated that the rat did not die within 24 h. The recall/sensitivity/true positive
508 rate = (number of true positives)/(number of correct predictions) and the false positive rate = (number
509 of false positives)/(number of correct predictions). These rates are calculated for $0 \leq \varepsilon_{crit} \leq 200$ ε -
510 units to produce the AUC-ROC curve in Fig 5B. An area under this curve that is close to 1 indicates
511 a model that can classify outcomes correctly. Here, the area under the curve was 0.98.

512

513 Since the experimental data in this study suggest significant differences between the OMT = 24-h and
514 the OMT > 24-h groups, simulations were conducted to determine whether the model could reveal
515 additional differences that may exist between these two groups. In Fig 6, a simulation was run for each

516 of the 27 different bacterial loads (B_{source}) administered to the rats in the validation data set (Fig 1B)
517 assuming that $\varepsilon_{crit} = 53$ ε -units (corresponding to the maximum accuracy determined in Fig 5A).
518 Simulations that correspond to a predicted OMT = 24 h are shown in blue and those corresponding to
519 an OMT > 24 h are shown in red. As observed in Fig 6, the OMT 24-h group was predicted to have
520 significantly higher bacteria, inflammatory, and damage levels. While there was a notable divide
521 between model-predicted septic and aseptic cases in terms of bacterial levels (high vs. near zero levels)
522 after approximately 36 h, there was no particularly notable divide between the predicted OMT = 24-h
523 (blue) and the septic members of the OMT > 24-h (red) groups.

524
525 The model was also used to give possible explanations for the lack of statistical difference among the
526 three OMT > 24-h groups. As shown in Fig 1B and Table S2, some rats with similar levels of initial
527 bacterial loads exhibited significantly different outcomes. For instance, Rats 11 and 20 received similar
528 initial bacterial loads, but Rat 11 died within 48 h while Rat 20 lived until 96 h. The model was used
529 to investigate these large discrepancies by varying model parameters and evaluating their impact on
530 system outcomes. For instance, these investigations showed that small changes in pathogen growth
531 rate (k_1) had a substantial effect on the predicted outcomes of the system. Fig 7 shows the model-
532 predicted impact of decreasing this parameter slightly, given similar initial bacterial loads of 163×10^6
533 bacteria in Rat 11 (red) and 172×10^6 bacteria in Rat 20 (cyan). Specifically, $k_1 = 1.27/h$ for Rat 11,
534 and $k_1 = 1.2/h$ for Rat 20. With these parameter values, the model predicted that Rat 11 died (i.e., its
535 damage levels crossed the critical damage threshold of $\varepsilon_{crit} = 53$ ε -units) at approximately 34 h
536 (corresponding to OMT = 48 h). Rat 20, however, was predicted to be healthy at 96 h (OMT = 96 h)
537 with a low steady state value of bacteria and zero steady state value of damage (since pro-inflammatory
538 levels never rise high enough to cause damage to the surrounding tissue). Similar changes in model

539 predicted outcomes were observed when other parameters, such as those governing the immune
540 response, were varied (see Section 3.4 and Fig 8).

541

542 **3.4 Outcome dependence on parameter values**

543 Fig 8 summarizes the dependence of stable outcomes (health is cyan, asepsis is blue, and sepsis is
544 red) on the number of bacteria in the fibrin clot (B_{source}), pathogen growth rate (k_1), strength of the
545 local immune response (k_2), and pro-inflammatory activation rate (v_1). As k_1 was increased or as k_2
546 was decreased, the number of bacteria that the system could handle and still recover decreased (Fig
547 8A and 8B). The dashed lines in the figures indicate the three levels of B_{source} that were administered
548 to the rats in the calibration data set. These multiple parameter bifurcation plots suggest that a
549 healthy recovery outcome was not possible for many (high) levels of B_{source} . For lower levels of
550 B_{source} , the model predicted that regions of healthy recovery become aseptic and then septic as the
551 pathogen growth rate was increased (Fig 8A) or the strength of the local immune response was
552 decreased (Fig 8B). As B_{source} was decreased, the width of the aseptic region decreased and
553 completely disappeared when $B_{source} = 6 \times 10^6$ bacteria. This suggests that, regardless of the value of
554 k_1 or k_2 , an aseptic outcome is not possible for a small enough initial bacterial load.

555

556 Parameter v_1 is the maximum activation rate of the pro-inflammatory response. As shown in Fig 8C,
557 there was a very narrow region (199×10^6 bacteria $< B_{source} < 201 \times 10^6$ bacteria) in which the model
558 predicted that increasing v_1 causes a change in stable outcome from septic death to healthy recovery
559 and then to aseptic death. This suggests that increasing the recruitment of pro-inflammatory cells and
560 mediators first helps then overwhelms the system. For higher levels of B_{source} ($B_{source} > 258 \times 10^6$
561 bacteria), a moderate activation rate ($v_1 = 0.08$ M-units/h) divides the septic region ($v_1 < 0.08$ M-

562 units/h) from the aseptic region ($v_1 > 0.08 M$ -units/h), suggesting that a highly responsive pro-
563 inflammatory activation rate leads to aseptic outcomes.

564

565 The nearly equal split between septic and aseptic cases shown in Fig 8C for $B_{source} > 258 \times 10^6$ can be
566 explained by the interactions between the bacteria and inflammatory response. The interaction term
567 involving BM in the bacteria equation (Eq. 1) was initially very small since not enough M had been
568 recruited. Thus, early dynamics for the bacteria equation were governed primarily by the remaining
569 non-interaction terms (which are almost entirely unrelated to v_1). If B values increased above a
570 (relatively low) threshold, the non-interaction terms became large (and positive) enough to outweigh
571 any of the mounting contributions from the interaction term. This means that resulting high values of
572 B depended on initial dynamics when M values were low and v_1 had only a minor impact. In
573 addition, if $B_{source} > 258 \times 10^6$ bacteria, bacterial levels approached a high steady state level,
574 regardless of the size of the interaction term. So, if $v_1 < 0.08 M$ -units/h (right boundary of septic
575 region in Fig 8C), the pro-inflammatory levels never grew large enough to outweigh the non-
576 interaction terms in Equation 1. If $v_1 > 0.08 M$ -units/h, however, then the pro-inflammatory levels
577 caused the interaction term in Equation 1 eventually to outweigh the non-interaction terms, and the
578 bacteria were eliminated. This elimination took place after the system attained high bacterial levels
579 and was independent of B_{source} so long as $B_{source} > 258 \times 10^6$ bacteria.

580

581 **4 Discussion**

582 In this study, a mathematical model of the immune response to a bacterial infection was developed
583 from previous inflammation models (16, 36, 46) and applied to an experimental study in which
584 variable doses of *E. Coli* were administered to rats. The model was calibrated to bacterial levels in

585 the rats at multiple time points following implantation of the *E. coli* fibrin clot. The model
586 successfully predicted outcomes of observed mortality times in 27 rats given several different initial
587 bacterial loads. The differences in model-predicted levels of bacteria, pro-inflammatory response,
588 anti-inflammatory response, and damage for rats with OMT = 24 h and rats with OMT > 24 h,
589 however, were not as large as expected. Thus, the model accurately predicts observed outcomes
590 when initial conditions are well-known, but predicting final outcomes based on data at early time
591 points is challenging when large uncertainty surrounds the appropriate initial conditions to use for
592 model or statistics-based predictions. The model also showed that variability in experimental
593 outcomes can result from variability in the pathogen growth rate, strength of the local immune
594 response, or maximum activation rate of the pro-inflammatory response, since small changes in these
595 parameter values generated large changes in system outcomes.

596

597 An important goal for mathematical models of disease is to yield accurate patient-specific outcomes.
598 Ideally, given early time course data on bacterial levels and cytokine levels in a patient, a model
599 could be used to predict whether that patient will follow a healthy recovery (resolving), septic, or
600 aseptic outcome. Then, depending on the forecasted outcome, appropriate countermeasures could be
601 prescribed, allowing for an efficient and accurate use of resources. In many studies, pure statistics
602 are used to predict the likely status or outcome of a given patient. Applying pure statistics to the
603 validation data set in this study (e.g., using a predictor that predicts death within 24 h if the initial
604 bacterial load exceeds a certain amount) would produce similar successful predictions but would not
605 be able to predict septic vs. aseptic outcomes, explain failed predictions, or reveal the underlying
606 system dynamics. While more complex statistics using more data per patient can help to improve the
607 accuracy of statistical methods, ultimately such methods still do not identify the mechanisms leading
608 to observed outcomes as mechanistic mathematical models do. An optimal theoretical approach for

609 understanding disease should include a combination of mathematical modeling and statistical
610 methods (67, 68). The study presented here provides an example of such a combined mathematical
611 and statistical approach.

612

613 ***4.1 Mathematical and statistical predictions***

614

615 Statistical analyses applied to the validation data set suggested no significant difference between the
616 bacterial levels in rats with observed mortality times of 48, 72, and 96 h. Therefore, this study
617 considered only two groups from the data set: rats that died before 24 h (OMT = 24 h) and rats that
618 died after 24 h (OMT > 24 h).

619

620 No clear separation among bacteria, inflammatory, or damage levels was predicted by the model for
621 the OMT = 24-h and OMT > 24-h groups. Interestingly, the model predicted very similar trajectories
622 for the pro- and anti-inflammatory response. For example, there was a tight grouping of the pro- and
623 anti-inflammatory response in the OMT = 24-h group. As a result, statistical models for this system
624 would have difficulty predicting whether a septic or aseptic outcome should be expected especially
625 due to the uncertainty associated with detecting when the infection begins to take hold. These model
626 predictions imply that that pro-inflammatory, anti-inflammatory, or bacterial levels at early time
627 points (e.g., 8 h) cannot be used to predict outcomes from a statistical perspective, thereby motivating
628 the need for a combined statistical and mechanistic modeling approach.

629

630 Modeling helps to determine the relative importance (and validity) of proposed mechanisms and
631 potential targets for successful interventions. For instance, the sensitivity analysis in this study
632 showed that the local immune response is important. Obtaining patient specific parameters for the
633 local immune response using well-designed measurements could improve parameter estimation,
634 mitigate uncertainty in initial conditions, and enable more accurate patient-specific model-generated
635 predictions regarding potential septic outcomes, corresponding dynamics, and proposed
636 treatments. Such measurement planning and usage rely on well-chosen statistical techniques and
637 could include both patient-specific measurements and/or general population measurements. In the
638 case of the latter, maps of parameter spaces for general populations could be generated and then a
639 few well-chosen measurements could be used to estimate the location of a specific patient in that
640 space and their patient-specific corresponding parameter values. In addition, future models could
641 make similar improvements in predictions by including mechanisms that involve specific (rather than
642 general) cytokines (25) or those involving spatial organization of the system (36).

643

644 The validation data set showed that similar bacterial loads led (in some cases) to significantly
645 different mortality times in rats. Just as previous models have demonstrated the impact of
646 stochasticity on model outcomes (34, 40), the current model demonstrated that experimental or
647 clinical variability in sepsis outcomes can be explained by very small differences in parameters
648 governing bacteria or the host response. Additionally, the different outcomes in two rats with nearly
649 identical bacterial loads could result from small differences in initial conditions due to underlying
650 stressors at the beginning of the experiment. As a result, in order to enable patient-specific care,
651 different parameter sets and/or initial conditions must be used for different individuals to capture
652 variability among patients.

653

654 **4.2 Comparison to prior mathematical modeling studies of sepsis**

655 Several sepsis modeling studies have been described previously. Kumar et al. (17) used a model
656 similar to the model developed in the current study to predict that sepsis may have multiple negative
657 outcomes (e.g., septic and aseptic death) that may require different treatment approaches. However,
658 their study did not explicitly incorporate any experimental data. Yamanaka et al. (69) created a
659 model founded on clinical data focused solely on septic shock, an important subset of sepsis.
660 McDaniel et al. (42) introduced a “whole-body” sepsis model (via the BioGears Physiology Engine)
661 to be used as an *in silico* septic simulator. While these and several other sepsis models (21, 23-25,
662 31, 33, 38-40, 70) have offered many useful insights, the present study emphasized the acute
663 inflammatory dynamics that take place during early sepsis development using a relatively simple and
664 novel modeling framework that can be used to identify the mechanisms that underly vastly different
665 outcomes despite nearly identical initial conditions. Notably, our results using experimental sepsis
666 induced in genetically identical rats support those of Cockrell et al. (40), who used an agent-based
667 model of human sepsis to suggest that mortality could occur under diverse conditions and influences
668 which in turn would defy stratification based on inflammation biomarkers.

669

670 **4.3 Limitations**

671 As is necessary in theoretical modeling, the model presented in this study applies simplifying
672 assumptions to make predictions about the average health status in a system. For example, several
673 immune system mediators are grouped together into two general populations for the pro- and anti-
674 inflammatory responses. Also, the model considered only virulent bacteria; non-virulent (e.g.,

675 probiotic) bacteria (46) were not included. Although additional model components could improve
676 predictions, the simplicity of this model allows for very useful analysis of the impact of parameters
677 and interactions on the health of a rat. The simplicity of the model, however, does limit the ability to
678 capture more complicated underlying dynamics. For instance, a single variable, ϵ_{crit} , is used to
679 predict outcomes based on system damage when outcomes likely depend on additional factors.
680 Similarly, differences between species are subsumed into a single parameter (B_s) when converting
681 bacteria-associated quantities from the human system developed by Reynolds et al. (16) to the rat
682 system considered in this study.

683

684 The model was calibrated using both quantitative data (bacterial levels at multiple time points) and
685 qualitative observations (coexistence of healthy/recovery/septic/aseptic steady states for some
686 parameter values). The data used in this study did not include measurements of cytokine levels, and
687 thus using data sets with both bacterial and cytokine levels could help to improve model calibration
688 and design. In addition, the validation data only included time points of 24, 48, 72, and 96 h. There
689 is probably a more continuous change in mortality outcomes, and thus a more accurate threshold for
690 death could be obtained given additional time point data. Finally, the model has been calibrated to
691 peritoneal injections that cause sepsis in rats. More experimental data would allow for more general
692 insights.

693

694 **4.4 Concluding remarks**

695

696 With complicated processes such as inflammation where hundreds of molecules, cells, and other
697 factors play roles, mathematical models are essential for providing a mechanistic understanding of
698 the system, as in the current sepsis study. This is especially true when very small differences in
699 initial conditions or parameter values in complex systems can have a major impact on outcome, as
700 illustrated in this study. Thus, model reduction is needed to facilitate analysis and interpretation. The
701 parsimonious model of sepsis presented here, after calibration, reproduced experimental results,
702 identified an inherent level of uncertainty associated with experimental data and associated
703 predictions, predicted trends as bacterial load, pathogen growth rate, strength of the local immune
704 response, and activation rate of the pro-inflammatory response were varied, and provided a
705 simplifying paradigm that can be used to understand the life vs. death outcomes for septic
706 individuals. As recent studies in blunt trauma (71), traumatic brain injury (72), and pediatric acute
707 liver failure (73, 74) have shown, a dichotomy in patient outcomes was observed as soon as
708 measurements were taken, suggesting that inflammation, regardless if it results from trauma, disease,
709 or sepsis, exhibits the same features illustrated in this work. Using mathematical modeling provides
710 an understanding of possible mechanisms that could explain such dichotomies in outcomes, in
711 contrast to methods solely based on statistical assessments of clusters or outcomes.

712

713

714

715

716

717

718

719

720 **Figure Captions**

721

722 **Fig 1. Experimental data sets used for model calibration and validation.** (A) The calibration
723 data set is depicted using closed circles (●) for each measured bacterial level. Bacterial
724 measurements were obtained for the following three initial bacterial loads: 1.28×10^8 bacteria
725 (cyan), 2.48×10^8 bacteria (blue), and 5.05×10^8 bacteria (red). Minimum and maximum bars and
726 lines connect the geometric means of the measurements at each time point. (B) The validation data
727 set includes the observed mortality time for twenty-seven rats injected with varying levels of bacteria
728 via an *E. coli*-impregnated fibrin clot (each measurement is represented with a ●). The bottom and
729 top of the box-and-whiskers plot indicate the edges of the first and third quartiles, respectively, and
730 the whiskers extend to the smallest and largest values in each group that are less than 2.7 within-
731 group standard deviations from the mean. The data points for Rat 11 and Rat 20 (Section 3.3) are
732 denoted by a red and cyan ●, respectively.

733

734 **Fig 2. Schematic illustrating bacteria-immune interactions among the four model populations.**
735 The model schematic shows the interactions between bacteria (B), pro-inflammatory response (M),
736 anti-inflammatory response (A), and damage levels (ε). The external infection is denoted by $D(t)$.
737 The arrow heads correspond to upregulation, and blunted (flat) arrow heads indicate downregulation.
738 This figure was adapted from (16).

739

740 **Fig 3. Validity of fitting the mathematical model to log-transformed data.** (A) Calibrating data set
741 (●) plotted with model-predicted bacterial dynamics over the experimental times considered (solid
742 curves). The following three initial bacterial loads were provided in the data set: 128×10^6 bacteria
743 (cyan), 248×10^6 bacteria (blue), and 505×10^6 bacteria (red). (B) Plot of the standardized residuals

744 for the given fit to log-transformed data. These plots demonstrate the validity of using log-
745 transformation and fitting via least squares.

746

747 **Fig 4.** Predicted dynamics for healthy recovery, septic, and aseptic outcomes as pathogen growth rate
748 is varied. Model predictions of bacteria (A), pro-inflammatory (B), anti-inflammatory (C), and damage
749 (D) levels as pathogen growth rate (k_1) was varied. Three different outcomes were predicted for an
750 initial bacterial infection of $B_{source} = 128 \times 10^6$ bacteria: healthy recovery ($k_1 = 1.2/\text{h}$, cyan), asepsis
751 ($k_1 = 1.3/\text{h}$, blue), and sepsis ($k_1 = 1.4/\text{h}$, red).

752

753 **Fig 5. Demonstrated accuracy of model predictions of health or disease outcomes.** (A) Model
754 prediction accuracy. The number of correct model predictions divided by the total number of
755 predictions (i.e., model prediction accuracy) is shown as a function of the critical damage level (ε_{crit}).
756 Relatively high levels of accuracy are attained for a large range of critical damage levels. (B) Area
757 under the curve-receiver operator characteristics curve. An area under this curve close to 1 indicates
758 the model is capable of classifying outcomes correctly. The area under the curve is 0.98.

759

760 **Fig 6.** Similarities in time dynamics predicted despite varying bacterial loads and mortality data for
761 27 rats. The model-predicted dynamics of the bacteria (A), pro-inflammatory (B), anti-inflammatory
762 (C), and damage (D) levels are shown for each of the rats from the validation data set. Blue curves
763 correspond to rats that had a predicted observed mortality time of 24 h, and red curves correspond to
764 rats that were predicted to survive for more than 24 h. The clustering of many of the trajectories

765 suggests that small uncertainties in the initial state of the system could lead to significantly different
766 systemic predictions.

767

768 **Fig 7. Small variations in system parameters produce significantly different outcomes**

769 **consistent with experimental measurements.** Comparison of the predicted dynamics for the
770 bacteria (A), pro-inflammatory (B), anti-inflammatory (C), and damage (D) dynamics for Rat 11
771 (red) and Rat 20 (cyan) using different parameter values. Parameters for Rat 11: $B_{source} = 163 \times 10^6$
772 bacteria, $k_1 = 1.27/h$. Parameters for Rat 20: $B_{source} = 172 \times 10^6$ bacteria, $k_1 = 1.2/h$. Despite similar
773 parameter values, the model predicts significantly different OMTs for Rat 11 (OMT = 48 h) and Rat
774 20 (OMT = 96 h). These OMTs are the same as those observed in the validation data set (Fig 1B). A
775 horizontal dashed line is included in panel D and corresponds to the critical damage level, $\varepsilon_{crit} = 53 \varepsilon$ -
776 units.

777

778 **Fig 8.** Varying bacterial and immune response parameters significantly impacts model predicted
779 outcomes. (A) Increasing the pathogen growth rate (k_1) turns healthy (cyan) outcomes into aseptic
780 (blue) and then septic (red) outcomes. (B) Increasing the strength of the local immune response (k_2)
781 turns septic outcomes into aseptic then healthy outcomes. (C) Increasing the pro-inflammatory
782 activation rate contributes to more aseptic outcomes and lowers the probability of a healthy outcome.
783 Dashed lines correspond to initial bacterial levels that were used in the experiments. The three
784 yellow \diamond 's in panel A indicate the three values of k_1 (1.2, 1.3, 1.4/h) that were simulated in Fig 4.
785 The two yellow \circ 's in panel A indicate the two values of k_1 (1.27 and 1.2/h) that were simulated in
786 Fig 7 for Rats 11 and 20.

787

788

789

Table 1: Model parameter values, units, definitions, and sources.

Parameter	Value	Unit	Description	Source
k_I	1 – 1.5	1/h	pathogen growth rate, 1.27 fitted/default	estimated
B_∞	0.737	10^6 cells/cm ³	pathogen carrying capacity	estimated
B_s	0.00083	1/cm ³	rescaling factor for bacterial levels	estimated
k_2	0.4 - 0.7	1/ M -units/h	rate at which non-specific local response eliminates pathogen, 0.6 default	(16)
s_l	0.005	M -units/h	source of non-specific local response	(16)
μ_l	0.002	1/h	decay of non-specific local response	(16)
k_3	0.01	1/(10^6 cells/cm ³)/h	rate at which the non-specific local response is exhausted by pathogen	(16)
k_5	1.8	1/ M -units/h	rate at which pro-inflammatory response consumes pathogen	(16)
k_A	7.08	1/ A -units	inhibition rate of the anti-inflammatory response	Adapted from (16, 21)
v_1	0 - 0.16	M -units/h	maximum activation rate of pro-inflammatory response , 0.08 default	(16, 21)
v_2	0.12	1/h	half-saturation of pro-inflammatory response	(16, 21)
k_M	0.01	1/ M -units/h	self-activation of pro-inflammatory response	(16, 21)
k_B	0.1	1/(10^6 cells/cm ³)/h	activation of pro-inflammatory response by pathogen	Adapted from (16, 21)
k_e	0.02	1/ ε -units/h	activation of pro-inflammatory response by damage	(16, 21)

μ_M	0.05	1/h	decay of pro-inflammatory response	(16, 21)
s_A	0.0125	A -units/h	source of anti-inflammatory response	(16, 21)
v_3	0.04	A -units/h	maximum production rate of anti-inflammatory response	(16, 21)
v_4	3640	M -units	Half-saturation of anti-inflammatory response	estimated
k_4	48	M -units/ ε -units	relative effectiveness of pro-inflammatory response and damage inducing the anti-inflammatory response	(16, 21)
μ_A	0.05	1/h	decay of the anti-inflammatory response	Comment in (16, 21)
τ	24	h	rate of recovery from damage	(46)
f	213	ε -units/ M -units/h	maximum rate of damage produced by the pro-inflammatory response	estimated
T	1	ε -units/h	threshold for damage	Comment in (46)
k_D	0.0344	1/h	decay of bacterial population in the clot (released into body)	estimated
B_C	407	10^6 cells	Number of bacteria a clot can hold	estimated
ε_{crit}	53	ε -units	critical damage level	estimated

790

791

792

793

794

795

796

797 **Conflict of Interest**

798 Yoram Vodovotz is a co-founder of, and stakeholder in, Immunetrics, Inc.

799

800 **Author Contributions**801 JA and YV both equally contributed as senior authors, with JA supervising the modeling components
802 and YV supervising the experiments. RN performed experiments and collected and compiled the
803 experimental data set. JA, JB, TB, AC and AT developed the model equations and analyzed model
804 behavior. JB finalized all model calibrations to experimental data and statistically analyzed model
805 fits and subsequent predictions. JB, JA, YV, and RN wrote the manuscript. All authors contributed
806 to the article and approved the submitted version.

807

808 **Funding**809 YV acknowledges NIH Grant U01EB021960. JA acknowledges NIH R01EY030851, NSF DMS-
810 1654019. JA and JB acknowledge NSF DMS-1852146. JB acknowledges NSF DMS-1951531.

811

812 **Data Availability Statement**813 All relevant data are plotted within figures in the manuscript and available in spreadsheet form from
814 supporting information files. All code used for producing simulations for this study may be found on
815 Github:816 https://github.com/jarobarb/code_for_sepsis.git.

817

818 **References**

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801-10.
2. Lelubre C, Vincent JL. Mechanisms and treatment of organ failure in sepsis. *Nature reviews Nephrology*. 2018;14(7):417-27.
3. Horiguchi H, Loftus TJ, Hawkins RB, Raymond SL, Stortz JA, Hollen MK, et al. Innate immunity in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome and its implications for therapy. *Frontiers in immunology*. 2018;9:595.
4. Grondman I, Pirvu A, Riza A, Ioana M, Netea MG. Biomarkers of inflammation and the etiology of sepsis. *Biochemical Society transactions*. 2020;48(1):1-14.
5. Chen XH, Yin YJ, Zhang JX. Sepsis and immune response. *World J Emerg Med*. 2011;2(2):88-92.
6. Delano MJ, Ward PA. The immune system's role in sepsis progression, resolution, and long-term outcome. *Immunol Rev*. 2016;274(1):330-53.

833 7. Buchman TG, Billiar TR, Elster E, Kirk AD, Rimawi RH, Vodovotz Y, et al. Precision
834 medicine for critical illness and injury. *Critical care medicine*. 2016;44(9):1635-8.

835 8. Day JD, Cockrell C, Namas R, Zamora R, An G, Vodovotz Y. Inflammation and disease:
836 Modelling and modulation of the inflammatory response to alleviate critical illness. *Current Opinion*
837 in Systems Biology. 2018;12:22-9.

838 9. Vodovotz Y, Csete M, Bartels J, Chang S, An G. Translational systems biology of
839 inflammation. *PLoS Comput Biol*. 2008;4:1-6.

840 10. Schorr CA, Dellinger RP. The Surviving Sepsis Campaign: past, present and future. *Trends*
841 *Mol Med*. 2014;20(4):192-4.

842 11. Yende S, D'Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, et al. Inflammatory markers
843 at hospital discharge predict subsequent mortality after pneumonia and sepsis. *American journal of*
844 *respiratory and critical care medicine*. 2008;177(11):1242-7.

845 12. Otto GP, Sossdorf M, Claus RA, Rödel J, Menge K, Reinhart K, et al. The late phase of sepsis
846 is characterized by an increased microbiological burden and death rate. *Critical care*. 2011;15(4):1-8.

847 13. Arens C, Bajwa S, Koch C, Siegler BH, Schneck E, Hecker A, et al. Sepsis-induced long-term
848 immune paralysis—results of a descriptive, explorative study. *Critical care*. 2016;20(1):1-11.

849 14. Nedeva C. Inflammation and Cell Death of the Innate and Adaptive Immune System during
850 Sepsis. *Biomolecules*. 2021;11(7):1011.

851 15. Vodovotz Y, Constantine G, Rubin J, Csete M, Voit EO, An G. Mechanistic simulations of
852 inflammation: current state and future prospects. *Math Biosci*. 2009;217(1):1-10.

853 16. Reynolds A, Rubin J, Clermont G, Day J, Vodovotz Y, Bard Ermentrout G. A reduced
854 mathematical model of the acute inflammatory response: I. Derivation of model and analysis of anti-
855 inflammation. *J Theor Biol*. 2006;242(1):220-36.

856 17. Kumar R, Clermont G, Vodovotz Y, Chow CC. The dynamics of acute inflammation. *J Theor*
857 *Biol*. 2004;230(2):145-55.

858 18. Clermont G, Bartels J, Kumar R, Constantine G, Vodovotz Y, Chow C. *In silico* design of
859 clinical trials: a method coming of age. *Crit Care Med*. 2004;32:2061-70.

860 19. Daun S, Rubin J, Vodovotz Y, Roy A, Parker R, Clermont G. An ensemble of models of the
861 acute inflammatory response to bacterial lipopolysaccharide in rats: Results from parameter space
862 reduction. *J Theor Biol*. 2008;253:843-53.

863 20. Kumar R, Chow CC, Bartels J, Clermont G, Vodovotz Y. A mathematical simulation of the
864 inflammatory response to anthrax infection. *Shock (Augusta, Ga)*. 2008;29:104-11.

865 21. Day J, Rubin J, Vodovotz Y, Chow CC, Reynolds A, Clermont G. A reduced mathematical
866 model of the acute inflammatory response II. Capturing scenarios of repeated endotoxin administration.
867 *J Theor Biol*. 2006;242(1):237-56.

868 22. Jarrett AM, Cogan NG, Shirtliff ME. Modelling the interaction between the host immune
869 response, bacterial dynamics and inflammatory damage in comparison with immunomodulation and
870 vaccination experiments. *Math Med Biol*. 2015;32(3):285-306.

871 23. Prince JM, Levy RM, Bartels J, Baratt A, Kane JM, 3rd, Lagoa C, et al. In silico and in vivo
872 approach to elucidate the inflammatory complexity of CD14-deficient mice. *Mol Med*. 2006;12(4-
873 6):88-96.

874 24. Vodovotz Y, Chow CC, Bartels J, Lagoa C, Prince JM, Levy RM, et al. In silico models of
875 acute inflammation in animals. *Shock*. 2006;26(3):235-44.

876 25. Chow CC, Clermont G, Kumar R, Lagoa C, Tawadrous Z, Gallo D, et al. The acute
877 inflammatory response in diverse shock states. *Shock*. 2005;24(1):74-84.

878 26. Foteinou PT, Calvano SE, Lowry SF, Androulakis IP. Modeling endotoxin-induced systemic
879 inflammation using an indirect response approach. *Math Biosci*. 2009;217(1):27-42.

880 27. Caudill L, Lynch F. A Mathematical Model of the Inflammatory Response to Pathogen
881 Challenge. *Bull Math Biol*. 2018;80(8):2242-71.

882 28. Smith AM, McCullers JA, Adler FR. Mathematical model of a three-stage innate immune
883 response to a pneumococcal lung infection. *J Theor Biol.* 2011;276(1):106-16.

884 29. Schirm S, Ahnert P, Wienhold S, Mueller-Redetzky H, Nouailles-Kursar G, Loeffler M, et al.
885 A Biomathematical Model of Pneumococcal Lung Infection and Antibiotic Treatment in Mice. *Plos
886 One.* 2016;11(5):e0156047.

887 30. Brady R. Mathematical modeling of the acute inflammatory response & cardiovascular
888 dynamics in young men 2017.

889 31. Shi Z, Wu CH, Ben-Arieh D, Simpson SQ. Mathematical Model of Innate and Adaptive
890 Immunity of Sepsis: A Modeling and Simulation Study of Infectious Disease. *Biomed Res Int.*
891 2015;2015:504259.

892 32. Mai M, Wang K, Huber G, Kirby M, Shattuck MD, O'Hern CS. Outcome Prediction in
893 Mathematical Models of Immune Response to Infection. *Plos One.* 2015;10(8):e0135861.

894 33. Song SO, Song SO, Hogg J, Peng ZY, Parker R, Kellum JA, et al. Ensemble models of
895 neutrophil trafficking in severe sepsis. *Plos Comput Biol.* 2012;8(3):e1002422.

896 34. Mavroudis PD, Scheff JD, Doyle JC, Vodovotz Y, Androulakis IP. The impact of stochasticity
897 and its control on a model of the inflammatory response. *Computation.* 2019;7(1):3.

898 35. Pilyugin SS, Antia R. Modeling immune responses with handling time. *Bull Math Biol.*
899 2000;62(5):869-90.

900 36. Barber J, Tronzo M, Harold Horvat C, Clermont G, Upperman J, Vodovotz Y, et al. A three-
901 dimensional mathematical and computational model of necrotizing enterocolitis. *J Theor Biol.*
902 2013;322:17-32.

903 37. Alt W, Lauffenburger DA. Transient behavior of a chemotaxis system modelling certain types
904 of tissue inflammation. *J Math Biol.* 1987;24(6):691-722.

905 38. An G. In silico experiments of existing and hypothetical cytokine-directed clinical trials using
906 agent-based modeling. *Crit Care Med.* 2004;32(10):2050-60.

907 39. An G. Agent-based computer simulation and sirs: building a bridge between basic science and
908 clinical trials. *Shock.* 2001;16(4):266-73.

909 40. Cockrell C, An G. Sepsis reconsidered: Identifying novel metrics for behavioral landscape
910 characterization with a high-performance computing implementation of an agent-based model. *J Theor
911 Biol.* 2017;430:157-68.

912 41. Minucci SB, Heise RL, Reynolds AM. Review of Mathematical Modeling of the Inflammatory
913 Response in Lung Infections and Injuries. *Frontiers in Applied Mathematics and Statistics.* 2020;6(36).

914 42. McDaniel M, Keller JM, White S, Baird A. A Whole-Body Mathematical Model of Sepsis
915 Progression and Treatment Designed in the BioGears Physiology Engine. *Front Physiol.* 2019;10:1321.

916 43. Ahrenholz DH, Simmons RL. Fibrin in peritonitis. I. Beneficial and adverse effects of fibrin in
917 experimental *E. coli* peritonitis. *Surgery.* 1980;88(1):41-7.

918 44. Namas R, Namas R, Lagoa C, Barclay D, Mi Q, Zamora R, et al. Hemoabsorption reprograms
919 inflammation in experimental Gram-negative septic fibrin peritonitis: Insights from *in vivo* and *in silico*
920 studies. *MolMed.* 2012;18:1366-74.

921 45. Öner M, Deveci Kocakoç İ. Jmasm 49: A compilation of some popular goodness of fit tests for
922 normal distribution: Their algorithms and matlab codes (matlab). *Journal of Modern Applied Statistical
923 Methods.* 2017;16(2):30.

924 46. Arciero JC, Ermentrout GB, Upperman JS, Vodovotz Y, Rubin JE. Using a mathematical model
925 to analyze the role of probiotics and inflammation in necrotizing enterocolitis. *PLoS One.*
926 2010;5(4):e10066.

927 47. Arciero J, Barber J, Kim M. Modeling Host–Pathogen Interactions in Necrotizing Enterocolitis.
928 Complex Systems and Computational Biology Approaches to Acute Inflammation: Springer; 2013. p.
929 231-64.

930 48. Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. *J Intern*
 931 *Med.* 2004;255(3):320-31.

932 49. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the
 933 immune arsenal. *Nature reviews Immunology.* 2005;5(4):331-42.

934 50. Arciero J, Bard Ermentrout G, Siggers R, Afrazi A, Hackam D, Vodovotz Y, et al. Modeling
 935 the interactions of bacteria and Toll-like receptor-mediated inflammation in necrotizing enterocolitis.
 936 *J Theor Biol.* 2013;321:83-99.

937 51. Kumar V. Pulmonary Innate Immune Response Determines the Outcome of Inflammation
 938 During Pneumonia and Sepsis-Associated Acute Lung Injury. *Front Immunol.* 2020;11:1722.

939 52. Qiu P, Liu Y, Zhang J. Review: the Role and Mechanisms of Macrophage Autophagy in Sepsis.
 940 *Inflammation.* 2019;42(1):6-19.

941 53. Cavaillon JM, Annane D. Compartmentalization of the inflammatory response in sepsis and
 942 SIRS. *J Endotoxin Res.* 2006;12(3):151-70.

943 54. Remick DG. Pathophysiology of sepsis. *The American journal of pathology.*
 944 2007;170(5):1435-44.

945 55. Ganusov VV. Strong Inference in Mathematical Modeling: A Method for Robust Science in
 946 the Twenty-First Century. *Front Microbiol.* 2016;7:1131.

947 56. Morikawa M, Deryck R, Miyazono K. TGF- β and the TGF- β Family: Context-Dependent
 948 Roles in Cell and Tissue Physiology. *Cold Spring Harb Perspect Biol.* 2016;8(5).

949 57. Isler P, de Rochemonteix BG, Songeon F, Boehringer N, Nicod LP. Interleukin-12 production
 950 by human alveolar macrophages is controlled by the autocrine production of interleukin-10. *Am J*
 951 *Respir Cell Mol Biol.* 1999;20(2):270-8.

952 58. Bacon GE, Kenny FM, Murdaugh HV, Richards C. Prolonged serum half-life of cortisol in
 953 renal failure. *Johns Hopkins Med J.* 1973;132(2):127-31.

954 59. Bocci V. Interleukins. Clinical pharmacokinetics and practical implications. *Clin*
 955 *Pharmacokinet.* 1991;21(4):274-84.

956 60. Fuchs AC, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, et al. Clinical,
 957 hematologic, and immunologic effects of interleukin-10 in humans. *J Clin Immunol.* 1996;16(5):291-
 958 303.

959 61. Huhn RD, Radwanski E, Gallo J, Affrime MB, Sabo R, Gonyo G, et al. Pharmacodynamics of
 960 subcutaneous recombinant human interleukin-10 in healthy volunteers. *Clin Pharmacol Ther.*
 961 1997;62(2):171-80.

962 62. Cobelli C, Distefano 3rd JJ. Parameter and structural identifiability concepts and ambiguities:
 963 a critical review and analysis. *American Journal of Physiology-Regulatory, Integrative and*
 964 *Comparative Physiology.* 1980;239(1):R7-R24.

965 63. Meshkat N, Eisenberg M, DiStefano III JJ. An algorithm for finding globally identifiable
 966 parameter combinations of nonlinear ODE models using Gröbner Bases. *Math Biosci.* 2009;222(2):61-
 967 72.

968 64. Karlsson J, Anguelova M, Jirstrand M. An efficient method for structural identifiability analysis
 969 of large dynamic systems. *IFAC proceedings volumes.* 2012;45(16):941-6.

970 65. Villaverde AF, Barreiro A, Papachristodoulou A. Structural identifiability of dynamic systems
 971 biology models. *Plos Comput Biol.* 2016;12(10):e1005153.

972 66. Brun R, Reichert, P., Kunsch, H.R. Practical identifiability analysis of large environmental
 973 simulation models. *Water Resour Res.* 2001;37(4):1015-30.

974 67. Albers DJ, Levine ME, Stuart A, Mamykina L, Gluckman B, Hripcak G. Mechanistic machine
 975 learning: how data assimilation leverages physiologic knowledge using Bayesian inference to forecast
 976 the future, infer the present, and phenotype. *J Am Med Inform Assoc.* 2018;25(10):1392-401.

977 68. Baker RE, Pena JM, Jayamohan J, Jerusalem A. Mechanistic models versus machine learning,
 978 a fight worth fighting for the biological community? *Biol Lett.* 2018;14(5).

979 69. Yamanaka Y, Uchida K, Akashi M, Watanabe Y, Yaguchi A, Shimamoto S, et al. Mathematical
980 modeling of septic shock based on clinical data. *Theor Biol Med Model*. 2019;16(1):5.

981 70. Zuev SM, Kingsmore SF, Gessler DD. Sepsis progression and outcome: a dynamical model.
982 *Theor Biol Med Model*. 2006;3:8.

983 71. Abboud AN, Namas RA, Ramadan M, Mi Q, Almahmoud K, Abdul-Malak O, et al.
984 Computational analysis supports an early, type 17 cell-associated divergence of blunt trauma survival
985 and mortality. *Critical care medicine*. 2016;44:e1074-e81.

986 72. Abboud A, Mi Q, Puccio A, Okonkwo D, Buliga M, Constantine G, et al. Inflammation
987 following traumatic brain injury in humans: Insights from data-driven and mechanistic models into
988 survival and death. *Frontiers in Pharmacology*. 2016;7(342).

989 73. Zamora R, Vodovotz Y, Mi Q, Barclay D, Yin J, Horslen S, et al. Data-driven modeling for
990 precision medicine in pediatric acute liver failure. *Molecular medicine* (Cambridge, Mass).
991 2016;22:821-9.

992 74. Zamora R, Barclay D, Yin J, Alonso EM, Leonis MA, Mi Q, et al. HMGB1 is a central driver
993 of dynamic pro-inflammatory networks in Pediatric Acute Liver Failure induced by acetaminophen.
994 *Scientific reports*. 2019;9(1):5971.

995